Forward Management’s Orexigen Therapeutics, Inc. OREX Stock Holding History

Forward Management’s Portfolio OREX Stock Details OREX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-26,960	Closed	-$1.63M	–	403
2015 Q1	$1.63M	Buy	+26,960	New	+$1.67M	0.1%	125
2014 Q3	–	Sell	-21,518	Closed	-$1.17M	–	436
2014 Q2	$1.17M	Sell	21,518 -13,988	-39%	-$813K	0.07%	138
2014 Q1	$2.18M	Buy	35,506 +14,571	+70%	+$986K	0.13%	104
2013 Q4	$1.15M	Buy	20,935 +2,522	+14%	+$142K	0.07%	134
2013 Q3	$1.19M	Buy	18,413 +10,185	+124%	+$690K	0.08%	138
2013 Q2	$480K	Buy	+8,228	New	+$506K	0.04%	217

Other funds holding OREX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

FCMI

Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Forward Management's OREX Position: Q2 2015 in Review

Forward Management sold out of Orexigen Therapeutics, Inc. (OREX) in Q2 2015, closing a stake of 26,960 shares — an estimated $1.63M sold.

Forward Management first reported a position in OREX in Q2 2013 and held it in 6 quarters. The position peaked at $2.18M in Q1 2014. 161 funds tracked by Wall St. Rank hold OREX as of Q2 2015.

Forward Management reported no remaining Orexigen Therapeutics, Inc. position as of Q2 2015 after selling out during the quarter.
Forward Management sold 26,960 Orexigen Therapeutics, Inc. shares in Q2 2015, an estimated $1.63M.
Forward Management first reported a position in Orexigen Therapeutics, Inc. in Q2 2013 and held it in 6 quarters.
Forward Management's Orexigen Therapeutics, Inc. position peaked at $2.18M in Q1 2014.
161 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q2 2015.

Based on Forward Management's 13F filing for Q2 2015, filed 11 Aug 2015.